β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)

@article{Bartus20162AdrenoceptorAA,
  title={$\beta$2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)},
  author={Raymond T. Bartus and Alexandre B{\'e}tourn{\'e} and Anthony S. Basile and Bethany L Peterson and Jonathan D. Glass and Nicholas M Boulis},
  journal={Neurobiology of Disease},
  year={2016},
  volume={85},
  pages={11-24}
}

Tables from this paper

The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?

An overview of the involvement of another very important and studied class of biological entities, G protein-coupled receptors (GPCRs), in the onset and progression of ALS is given to give an overview of what has been already discovered on the topic.

Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes

Results indicate that β-agonist stimulation is a novel therapeutic strategy for SBMA, and improves muscle pathology, attenuated the glycolytic-to-oxidative metabolic alterations occurring in SBMA muscles and induced hypertrophy of both glyCOlytic and oxidative fibers.

Adrenoceptors Modulate Cholinergic Synaptic Transmission at the Neuromuscular Junction

The elucidation of the molecular mechanisms by which the clinically relevant adrenoceptor activators and blockers regulate quantal acetylcholine release from the presynaptic nerve terminals and postsynaptic sensitivity may help in the design of highly effective and well-tolerated sympathomimetics for treating a number of neurodegenerative diseases accompanied by synaptic defects.

Could Sirtuin Activities Modify ALS Onset and Progression?

  • B. Tang
  • Biology
    Cellular and Molecular Neurobiology
  • 2016
It is important that the potentially beneficial effect of Sirtuins in ALS disease onset and progression are assessed in ALS models with TDP-43, FUS, and C9orf72 mutations.

Neuromuscular junction degeneration in muscle wasting

Basic research has revealed that maintenance of neuromuscular junctions and a few signaling pathways are important in the context of age-dependent and other forms of muscle wasting.

β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure

An animal model of acetylcholine receptor deficiency syndrome is used to show that beta-2 adrenergic receptor agonists ameliorate the damage to neuromuscular junction structure caused by prolonged anticholinesterase medication, and thereby counteract the decline in efficacy.

Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities

New knowledge on the extraction and characterization of bioactive human AD brain oAβ and the mechanisms by which they cause hippocampal synaptic dysfunction are reviewed to suggest a multi-target approach for the treatment of AD.

Adrenoceptors at the Frog Neuromuscular Junction: an Immunohistochemical Study

The presence of different adrenoceptors at isolated preparations of frog cutaneous pectoris muscle by using methods of immunohistochemistry expands the understanding of the endogenous mechanisms of cholinergic neurotransmission regulation and elucidates the aspects of the mechanisms of action of adrenergic agonists.

&agr;‐Cedrene, a Newly Identified Ligand of MOR23, Increases Skeletal Muscle Mass and Strength

SCOPE Skeletal muscle atrophy is a common and debilitating condition that lacks an effective therapy. In this study, the effects of α-cedrene are tested, a natural ligand of mouse olfactory receptor

α-Ionone attenuates high-fat diet-induced skeletal muscle wasting in mice via activation of cAMP signaling.

It is found that α-ionone not only stimulated myogenesis but also attenuated palmitic-acid-induced atrophy of cultured skeletal myotubes, as evidenced by an increased myotube diameter and length, fusion index, and cellular protein content.

References

SHOWING 1-10 OF 137 REFERENCES

β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.

Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?

The primary objectives of the current review are to assess the mechanisms, both molecular and cell-associated, that may limit the anti-inflammatory efficacy of β2-agonists and to evaluate pharmacological strategies that may overcome these limitations.

A pilot trial with clenbuterol in amyotrophic lateral sclerosis

  • G. Soraru'E. Pegoraro C. Angelini
  • Medicine
    Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
  • 2006
This study was designed to test the safety and efficacy of clenbuterol in ALS patients already treated with riluzole and found that beta agonists may positively influence muscle bulk and strength in humans.

Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.

The physiological significance ofbeta-adrenergic signaling in skeletal muscle is described and the proposed beneficial effects of beta-agonist administration on skeletal muscle along with some of the less desirable cardiovascular effects are examined.

β2-Adrenergic Receptor Activation Prevents Rodent Dopaminergic Neurotoxicity by Inhibiting Microglia via a Novel Signaling Pathway

Results demonstrate that administration of extremely low doses of salmeterol exhibit potent neuroprotective effects by inhibiting microglial cell activation through a β2AR/β-arrestin2–dependent but cAMP/protein kinase A-independent pathway.

β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome

A role for IGF1 and other growth factor deficits as an underlying mechanism of Rett syndrome is supported and β2-adrenergic receptor agonists are introduced as potential therapeutic agents for the treatment of the disorder.

β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.

...